Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 09:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Latest news
Date Title
<1m agoDJJ.P. Morgan Found Hackers After Finding Breach of Race Website -- Update
1m ago INSD BUIL : INSPIRED BUILDERS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
1m ago VACON : Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act
1m ago TESCO : Without a plan, junk status looms for Tesco - Moody's
2m ago ZIMPLATS : Reports 13 Percent Slump in Output
2m ago HUB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
2m ago Tropo and Amdocs Partner to Deliver Next Generation Communications APIs to Developers
2m ago MEDICX FUND : Investment Adviser Name Change
2m ago CABINET OF MINISTERS OF UKRAINE : PM requires to make an urgent decision on providing power plants with coal and prevent rolling blackouts
2m ago XL : Announces Quarterly Dividend of $0.16 Per Ordinary Share and Dividend of $8.5563 Per Series D Preference Ordinary Share
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Angola brings oil firm Sonangol into local BES bank
AVIV REIT : Omega Healthcare Investors and Aviv REIT to Merge Creating Premier $10Bn Skilled Nursing Facility REIT
AEGERION PHARMACEUTICALS : tops 3Q profit forecasts
MONEYGRAM : Ooredoo Mobile Money Customers Can Now Send Money Directly to M-Pesa Wallets in Kenya
BOTTOMLINE TECHNOLOGIES : Rule of law and single-party state can coexist, says scholars
Most Read News
1d ago ENERGEN : tops Street 3Q forecasts
1d ago CHINA MENGNIU DAIRY : Mengniu and Danone Strengthen Strategic Alliance as Danone Subscribes to a Private Placement by Yashili
4h ago BNP shakes off impact of U.S. fine, returns to profit
1d ago FLUOR NEW : ICA Fluor Awarded Fabrication Contract for Shell’s Heavy Oil Extraction Project in Canada
1d ago Hiring business drives LinkedIn's revenue beat
Most recommended articles
1m ago TESCO : Without a plan, junk status looms for Tesco - Moody's
3m ago THE WEEKLY VOLUME REPORT : USD Surges, Volume Begins to Come Back
11m ago TSX jumps on BOJ stimulus move; gold miners dive
13m ago WALL STREET STOCK EXCHANGE : Wall St. rallied broadly as BOJ ramps up stimulus
13m ago Barclays confident it will exceed Bank of England's leverage ratio demand
Dynamic quotes  
ON
| OFF